Clinical Trials Browser

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05812807 2026-04-07

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Phase 3 Recruiting

1,295 enrolled

Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT06604858 2026-04-07

TELESCOPE

Phase 2 Active not recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05286437 2026-04-06

LaPemERLA

Phase 2 Recruiting

40 enrolled

Breast

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Phase 2 Active not recruiting

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT06112379 2026-04-02

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Phase 3 Active not recruiting

1,902 enrolled

Breast

Breast Neoplasms

NCT06312176 2026-04-02

MK-2870-010

Phase 3 Recruiting

1,200 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

428 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT06103864 2026-03-31

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

625 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03449238 2026-03-30

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03546686 2026-03-27

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Phase 2 Active not recruiting

51 enrolled

Breast

Breast Neoplasms

NCT04234113 2026-03-27

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Phase 1 Terminated

115 enrolled 43 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Thymus Neoplasms, Thyroid Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT07218003 2026-03-23

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Enrolling by invitation

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms